secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2024-11-08T23:59:59+00:00
Accession:  0000950170-24-123681
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Q3 core rev $71.7M (+9% YoY), GAAP loss $0.48, non-GAAP EPS $0.31; guides FY core rev $280M
--------------------------------------------------------------------------------

- Total revenue $71.7M, core revenue (ex-COVID) $71.7M, up 9% YoY.
- GAAP net loss $14.6M ($0.48 per share); non-GAAP net income $9.4M ($0.31 per share).
- Adjusted EBITDA income $0.4M; cash and marketable securities $815.4M.
- Reiterated FY2024 core revenue guidance of $280M; improved EPS guidance for 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017024123681/0000950170-24-123681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017024123681/flgt-20241108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer